# Sunil Health (NSE: SUNLOC) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SUNLOC · Pivot · prices to 21 Oct 2026

Sunil Health (NSE: SUNLOC) closed at ₹65.00 on 21 Oct 2026. With a market capitalisation of ₹67 Cr, it ranks 2908th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 16.6× trailing earnings, against a return on equity of 5.8% in FY26. Its 52-week range is ₹63.21 (21 Oct 2026) to ₹82.00 (1 Sep 2026); the last close is 20.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹20 Cr (−7.0% year on year) and net profit ₹2 Cr (+322.2%), on a consolidated basis. Promoters held 73.53% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹65.00 |
| Market cap | ₹67 Cr |
| P/E (trailing) | 16.6 |
| ROE | 5.8% (FY26) |
| ROCE | 8.7% (FY26) |
| Debt to equity | 0.8 |
| 52-week high | ₹82.00 (1 Sep 2026) |
| 52-week low | ₹63.21 (21 Oct 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹20 Cr | −7.0% | ₹2 Cr | +322.2% | ₹1.48 |
| Q3 FY26 | ₹22 Cr | +6.7% | ₹1 Cr | — | ₹0.57 |
| Q2 FY26 | ₹24 Cr | +16.1% | ₹1 Cr | — | ₹0.97 |
| Q1 FY26 | ₹23 Cr | +5.3% | ₹1 Cr | — | ₹0.89 |
| Q4 FY25 | ₹21 Cr | −0.5% | ₹0 Cr | +140.0% | ₹0.35 |
| Q3 FY25 | ₹20 Cr | −9.7% | −₹1 Cr | — | −₹0.53 |
| Q2 FY25 | ₹20 Cr | −14.5% | −₹1 Cr | — | −₹0.53 |
| Q1 FY25 | ₹22 Cr | −4.5% | −₹1 Cr | — | −₹0.67 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹83 Cr | −₹1 Cr |
| FY24 | ₹90 Cr | −₹2 Cr |
| FY23 | ₹110 Cr | ₹7 Cr |
| FY22 | ₹119 Cr | ₹6 Cr |
| FY21 | ₹90 Cr | −₹1 Cr |
| FY20 | ₹70 Cr | −₹5 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 73.53%
- Domestic institutions: 0.10%
- Non-institutions: 26.37%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Source Natural](https://app.pivotnow.in/stock/SOURCENTRL) | — | ₹70 Cr | — | — |
| [Asston Pharma](https://app.pivotnow.in/stock/APL) | — | ₹69 Cr | — | — |
| [Fervent Synergi](https://app.pivotnow.in/stock/FERVENTSYN) | — | ₹68 Cr | — | — |
| [Samrat Pharma](https://app.pivotnow.in/stock/SAMRATPH) | — | ₹61 Cr | — | — |
| [Royal Sense](https://app.pivotnow.in/stock/ROYAL) | — | ₹59 Cr | — | — |
| [Bacil Pharma](https://app.pivotnow.in/stock/BACPHAR) | — | ₹58 Cr | — | — |

## Questions and answers

### What is the share price of Sunil Health today?

Sunil Health (NSE: SUNLOC) last closed at ₹65.00 on 21 Oct 2026. Its 52-week high is ₹82.00 and its 52-week low is ₹63.21.

### What is the market cap of Sunil Health?

Sunil Health's market capitalisation is ₹67 Cr (₹67 Cr) at the 22 Oct 2026 close, ranking 2908th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sunil Health?

Sunil Health trades at a trailing P/E of 16.6.

### What is the ROE and ROCE of Sunil Health?

Return on equity was 5.8% in FY26 and return on capital employed was 8.7% in FY26 (consolidated figures).

### Is Sunil Health a debt-free company?

No. Sunil Health's debt-to-equity ratio was 0.8 in FY26, with total debt of ₹16 Cr.

### What were Sunil Health's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Sunil Health reported revenue of ₹20 Cr, −7.0% year on year, and net profit of ₹2 Cr, +322.2% year on year.

### What is the shareholding pattern of Sunil Health?

As of 30 Jun 2026: promoters 73.53%, domestic institutions 0.10%, non-institutions 26.37%.

### Who are Sunil Health's competitors?

The listed Pharma & Healthcare companies closest to Sunil Health by market cap are Source Natural, Asston Pharma, Fervent Synergi, Samrat Pharma, Royal Sense and Bacil Pharma.

### Is Sunil Health a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sunil Health's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUNLOC against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.